A promising targeted gene delivery system: Folate-modified dexamethasone-conjugated solid lipid nanoparticles

Figures & data

Figure 1. General reaction scheme for synthesis of Fa-PEG-PE.

Figure 2. Preparation of Fa-PEG-PE modified SLNs/pEGFP.

Figure 3. Optimization of the modification ratios of Fa-PEG-PE to SLNs/DNA.

Table 1. Particle size, zeta potential and gene loading quantity of different vectors.

Characteristics Samples	Mean particle size (nm)	Polydispersity index (PDI)	Zeta potential (mV)	Gene loading quantity (%)
SLNs	97.6 ± 2.9	0.11 ± 0.04	+39.3 ± 2.6	0
SLNs/pEGFP	138.6 ± 3.2	0.16 ± 0.03	+28.4 ± 2.2	90.5
Fa-SLNs/pEGFP	203.4 ± 4.7	0.15 ± 0.02	+16.3 ± 1.8	89.9

Figure 4. The in vitro release profiles of Fa-SLNs/pEGFP and SLNs/pEGFP.

Figure 5. In vitro cytotoxicity evaluation of Fa-SLNs/pEGFP and SLNs/pEGFP.

Figure 6. Quantitation of in vivo transfection efficiencies of Fa-SLNs/pEGFP and other vectors at 24, 48, and 72 h post-transfection.